New England Surgical Society (NESS)
Search NESS
  Home
  Annual Meeting
  Annual Resident and Fellow Research Day
  Members
      Member Directory
      Members Only
  Scholars Foundation
  Job Board
  Awards
  Journal of the American College of Surgeons
  Newsletters
  Committees
  Contact NESS

 

Cystic neoplasms of pancreas: Long-Term Outcomes With Surgical Therapy

Hiromichi Ito, Evan Matros, Stanley W Ashley, Michael J Zinner, Edward E Whang
Brigham and Women's Hospital, Boston, MA

Objective: The aims of this study were to evaluate outcomes associated with the surgical management of cystic neoplasms of pancreas and to determine clinico-pathological factors associated with malignant histology.
Design:Retrospective case series.
Setting:Tertiary academic medical center.
Patients:109 patients with pancreatic cystic neoplasm were treated surgically. Mean patient age was 54 years, and 78% were female.
Main Outcome Measures:
Survival was analyzed using the Kaplan-Meier method and Log-Rank test. Median follow-up was 32 months (0-150 months).
Results:Of the 109 patients, 45 had a mucinous cystic neoplasm (MCN), 30 had an intraductal papillary mucinous neoplasm (IPMN) and 17 had a serous cystic neoplasm (SCN). Invasive cancer was found in 22%, 23% and 0% of MCN, IPMN, and SCN, respectively. The presence of invasive foci was associated with older patient age (62 years vs. 53 years, p=0.03) but not with tumor size, or presence of symptoms. 5 of 17 patients with invasive foci developed tumor recurrence, whereas none of the patients without invasion developed recurrence. The overall 5-year survival rates of patients with MCN, IPMN and SCN were 86%, 90% and 94%, respectively. The corresponding survival rates of patients with MCN and IPMN with invasive foci were 41% and 56%, respectively.
Conclusions:The presence of invasive foci in pancreatic cystic neoplasms, associated with recurrence and poor survival, remains difficult to predict preoperatively.

Back to Final Program

 

Copyright © 2018 New England Surgical Society. All Rights Reserved.
Read Privacy Policy.